Goldstein David S, Eldadah Basil A, Holmes Courtney, Pechnik Sandra, Moak Jeffrey, Saleem Ahmed, Sharabi Yehonatan
Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1620, USA.
Hypertension. 2005 Dec;46(6):1333-9. doi: 10.1161/01.HYP.0000188052.69549.e4. Epub 2005 Oct 10.
Patients with Parkinson disease often have orthostatic hypotension. Neurocirculatory abnormalities underlying orthostatic hypotension might reflect levodopa treatment. Sixty-six Parkinson disease patients (36 with orthostatic hypotension, 15 off and 21 on levodopa; 30 without orthostatic hypotension) had tests of reflexive cardiovagal gain (decrease in interbeat interval per unit decrease in systolic pressure during the Valsalva maneuver; orthostatic increase in heart rate per unit decrease in pressure); reflexive sympathoneural function (decrease in pressure during the Valsalva maneuver; orthostatic increment in plasma norepinephrine); and cardiac and extracardiac noradrenergic innervation (septal myocardial 6-[18F]fluorodopamine-derived radioactivity; supine plasma norepinephrine). Severity of orthostatic hypotension did not differ between the levodopa-untreated and levodopa-treated groups with Parkinson disease and orthostatic hypotension (-52+/-6 [SEM] versus -49+/-5 mm Hg systolic). The 2 groups had similarly low reflexive cardiovagal gain (0.84+/-0.23 versus 1.33+/-0.35 ms/mm Hg during Valsalva; 0.43+/-0.09 versus 0.27+/-0.06 bpm/mm Hg during orthostasis); and had similarly attenuated reflexive sympathoneural responses (97+/-29 versus 71+/-23 pg/mL during orthostasis; -82+/-10 versus -73+/-8 mm Hg during Valsalva). In patients off levodopa, plasma norepinephrine was lower in those with (193+/-19 pg/mL) than without (348+/-46 pg/mL) orthostatic hypotension. Low values for reflexive cardiovagal gain, sympathoneural responses, and noradrenergic innervation were strongly related to orthostatic hypotension. Parkinson disease with orthostatic hypotension features reflexive cardiovagal and sympathoneural failure and cardiac and partial extracardiac sympathetic denervation, independent of levodopa treatment.
帕金森病患者常伴有体位性低血压。体位性低血压潜在的神经循环异常可能反映左旋多巴治疗情况。66例帕金森病患者(36例伴有体位性低血压,其中15例未服用左旋多巴,21例服用左旋多巴;30例无体位性低血压)接受了反射性心迷走神经增益测试(瓦尔萨尔瓦动作期间收缩压每下降单位值时心跳间期的减少;体位性低血压时压力每下降单位值时心率的增加);反射性交感神经功能测试(瓦尔萨尔瓦动作期间的压力下降;体位性低血压时血浆去甲肾上腺素的增加);以及心脏和心脏外去甲肾上腺素能神经支配测试(间隔心肌6-[18F]氟多巴胺衍生的放射性;仰卧位血浆去甲肾上腺素)。帕金森病伴体位性低血压患者中,未服用左旋多巴组和服用左旋多巴组的体位性低血压严重程度无差异(收缩压分别为-52±6[标准误]与-49±5mmHg)。两组的反射性心迷走神经增益同样较低(瓦尔萨尔瓦动作期间分别为0.84±0.23与1.33±0.35ms/mm Hg;体位性低血压期间分别为0.43±0.09与0.27±0.06bpm/mm Hg);反射性交感神经反应同样减弱(体位性低血压期间分别为97±29与71±23pg/mL;瓦尔萨尔瓦动作期间分别为-82±10与-73±8mmHg)。未服用左旋多巴的患者中,伴有体位性低血压者的血浆去甲肾上腺素水平(193±19pg/mL)低于无体位性低血压者(348±46pg/mL)。反射性心迷走神经增益、交感神经反应及去甲肾上腺素能神经支配的低值与体位性低血压密切相关。伴有体位性低血压的帕金森病具有反射性心迷走神经和交感神经功能衰竭以及心脏和部分心脏外交感神经去神经支配的特征,与左旋多巴治疗无关。